Targeted therapy for breast cancer prevention

With a better understanding of the etiology of breast cancer, molecularly targeted drugs have been developed and are being testing for the treatment and prevention of breast cancer. Targeted drugs that inhibit the estrogen receptor or estrogen-activated pathways include the selective estrogen recep...

Full description

Bibliographic Details
Published in:	Frontiers in Oncology
Main Authors:	Petra eden Hollander, Michelle I. Savage, Powel H. Brown
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2013-09-01
Subjects:	Breast Cancer therapy prevention TNBC
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fonc.2013.00250/full

Similar Items

Targeting nuclear hormone receptors for the prevention of breast cancer
by: Cassandra L. Moyer, et al.
Published: (2023-07-01)

Trop2-targeted therapy in breast cancer
by: Yixuan Hu, et al.
Published: (2024-08-01)

Outcome of Triple Negative Breast Cancer(TNBC) as compared to other breast cancers in Bir Hospital, National Academy of Medical Sciences
by: Anip Joshi, et al.
Published: (2024-11-01)

Long-Term Breastfeeding: Protective Effects Against Triple-Negative Breast Cancer and the Role of the Breast Microbiota
by: Julia Sierra-Roca, et al.
Published: (2025-09-01)

Current Photoactive Molecules for Targeted Therapy of Triple-Negative Breast Cancer
by: Cristina J. Dias, et al.
Published: (2021-12-01)

Editorial: Recent advancements in neoadjuvant chemotherapy for specific breast cancer subtypes
by: Sirin A. Adham, et al.
Published: (2022-12-01)

Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
by: Dey Nandini, et al.
Published: (2021-05-01)

Rationally Designed Ruthenium Complexes for Breast Cancer Therapy
by: Golara Golbaghi, et al.
Published: (2020-01-01)

Evaluation of tumor-infiltrating lymphocytes (TILs) in molecular subtypes of an Indian cohort of breast cancer patients
by: Pooja M. Vaid, et al.
Published: (2022-11-01)

Metastatic Triple Negative Breast Cancer: The New Era of Thinking
by: Mohammed Amrallah A., et al.
Published: (2021-05-01)

The application of exosomes in the treatment of triple-negative breast cancer
by: John W. Weaver, et al.
Published: (2022-11-01)

Phytochemicals in Breast Cancer Prevention and Therapy: Mechanisms, Efficacy, and Future Prospects
by: Neha Kodali, et al.
Published: (2025-07-01)

Unraveling the protein kinase C/NDRG1 signaling network in breast cancer
by: C. Saponaro, et al.
Published: (2024-12-01)

Emergence of Nanotechnology as a Powerful Cavalry against Triple-Negative Breast Cancer (TNBC)
by: Aiswarya Chaudhuri, et al.
Published: (2022-04-01)

Triple-negative breast cancer: from none to multiple therapeutic targets in two decades
by: Filomena Marino Carvalho
Published: (2023-11-01)

Combination of Talazoparib and Calcitriol Enhanced Anticancer Effect in Triple−Negative Breast Cancer Cell Lines
by: Fu Hou Wong, et al.
Published: (2022-08-01)

LRP-1 Matricellular Receptor Involvement in Triple Negative Breast Cancer Tumor Angiogenesis
by: Océane Campion, et al.
Published: (2021-10-01)

Novel combination therapy of osimertinib and Tupichinol E in triple-negative breast cancer: Targeting EGFR and CDK4/6 pathways
by: Adyasa Samantaray, et al.
Published: (2025-06-01)

Editorial: Targeting triple negative breast cancer by natural compounds
by: Shashank Kumar, et al.
Published: (2023-03-01)

Breast Cancer Treatments: Drugs Targeting the PI3K/AKT/mTOR Pathway, TNBC Therapy and Future Directions: A Review
by: Klaudia Dynarowicz, et al.
Published: (2025-10-01)

MYC-Driven Pathways in Breast Cancer Subtypes
by: Yassi Fallah, et al.
Published: (2017-07-01)

Cold-inducible RNA-binding protein is associated with subtype-specific breast cancer patient outcomes
by: Matthew Dankner, et al.
Published: (2025-08-01)

Antiproliferative effects of cetuximab on triple negative breast cancer cell line MDA-MB-231
by: İdil Çetin
Published: (2020-09-01)

Overcoming acquired resistance to HSP90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer
by: Nuramalina H. Mumin, et al.
Published: (2019-01-01)

Current Immunotherapy Treatments of Primary Breast Cancer Subtypes
by: Savannah R. Brown, et al.
Published: (2024-04-01)

DSTYK Enhances Chemoresistance in Triple-Negative Breast Cancer Cells
by: Stella C. Ogbu, et al.
Published: (2021-12-01)

Immune Landscape of Breast Cancers
by: Divya Nagarajan, et al.
Published: (2018-02-01)

Targeting erbB Pathways in Breast Cancer: Dual Kinase Inhibition for Brain Metastasis and Prevention of p185HER2/Neu Tumor Development
by: Goel PN, et al.
Published: (2024-10-01)

Metformin-Based Combination Approaches for Triple-Negative Breast Cancer
by: Zaid Sirhan, et al.
Published: (2025-04-01)

Dihydropyrazole-Carbohydrazide Derivatives with Dual Activity as Antioxidant and Anti-Proliferative Drugs on Breast Cancer Targeting the HDAC6
by: Irving Balbuena-Rebolledo, et al.
Published: (2022-05-01)

Ezetimibe inhibits triple-negative breast cancer proliferation and promotes cell cycle arrest by targeting the PDGFR/AKT pathway
by: Qinyu He, et al.
Published: (2023-11-01)

Molecular profiling of breast cancer methylation pattern in triple negative versus non- triple negative breast cancer
by: Marwa Mohanad, et al.
Published: (2025-02-01)

Classifying Breast Cancer Metastasis Based on Imaging of Tumor Primary and Tumor Biology
by: Barbara Awad, et al.
Published: (2023-01-01)

Single-Cell Transcriptome Analysis Revealed Heterogeneity and Identified Novel Therapeutic Targets for Breast Cancer Subtypes
by: Radhakrishnan Vishnubalaji, et al.
Published: (2023-04-01)

Correlation between the CEM imaging characteristics and different molecular subtypes of breast cancer
by: Na Li, et al.
Published: (2023-12-01)

Targeting the CXCR4/CXCL12 Axis to Overcome Drug Resistance in Triple-Negative Breast Cancer
by: Desh Deepak Singh, et al.
Published: (2025-09-01)

Knowledge mapping of ultrasound technology and triple-negative breast cancer: a visual and bibliometric analysis
by: Yonglin Wan, et al.
Published: (2025-07-01)

USP22 supports the aggressive behavior of basal-like breast cancer by stimulating cellular respiration
by: Evangelos Prokakis, et al.
Published: (2024-02-01)

Ethnic disparities in the immune microenvironment of triple negative breast cancer and its role in therapeutic outcomes
by: Kelsee K. Zajac, et al.
Published: (2023-09-01)

Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer
by: Miquel Ensenyat-Mendez, et al.
Published: (2021-06-01)